ORPHA:280065
Calciphylaxis cutis
Publications
30
34.8th percentile
Trials
0
Interventional, condition-specific
Researchers
185
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, life-threatening, non-inflammatory vasculopathy characterized clinically by and painful skin lesions associated with calcification of cutaneous arterial microvessels. Calciphylaxis predominantly affects patients with end-stage kidney disease (ESKD) on dialysis.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017216
- UMLS:C4274083
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
30 matched papers (17 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 13 for broader category calciphylaxis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
30
30 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
30 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
17 in the last 10 years · high confidence · 34.8th percentile (publications denominator)
Phrase hits: 30 · MeSH hits: 0
Who's working on it?
185
Distinct author names in 30 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Gomez EA2 papers · 2018
Departamento de Parasitologia y Medicina Tropical, Carrera de Medicina, Facultad de Ciencias Medicas, Universidad Catolica de Santiago de Guayaquil, Guayaquil, Ecuador; Leishmaniasis Project, Facultad de Ciencias Medicas, Universidad Catolica de Santiago de Guayaquil, Guayaquil, Ecuador; Ministerio de Salud Publica, Guayaquil, Ecuador.
Papers in Europe PMC - 02Hashiguchi Y2 papers · 2018
Departamento de Parasitologia y Medicina Tropical, Carrera de Medicina, Facultad de Ciencias Medicas, Universidad Catolica de Santiago de Guayaquil, Guayaquil, Ecuador; Leishmaniasis Project, Facultad de Ciencias Medicas, Universidad Catolica de Santiago de Guayaquil, Guayaquil, Ecuador; Department of Parasitology, Kochi Medical School, Kochi University, Kochi, Japan. Electronic address: yhashiguchi42@yahoo.co.jp.
Papers in Europe PMC - 03Kato H2 papers · 2018
Division of Medical Zoology, Department of Infection and Immunity, School of Medicine, Jichi Medical University, Tochigi, Japan.
Papers in Europe PMC - 04Abdulwahed SR1 paper · 2009Papers in Europe PMC
- 05Achebe I1 paper · 2020
Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, USA.
Papers in Europe PMC - 06Achenbach H1 paper · 2003Papers in Europe PMC
- 07
- 08Agnihotri P1 paper · 2024
Shri Balaji Institute of Medical Science, Raipur, India
Papers in Europe PMC - 09Agostini M1 paper · 2012
Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, São Paulo, Brazil. michelleagostini@uol.com.br
Papers in Europe PMC - 10Al-Shraideh Y1 paper · 2021
Department of Urology, University of Illinois College of Medicine-Peoria, Order of Saint Francis, Peoria, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 13 trials are registered for calciphylaxis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
13 interventional trials matched calciphylaxis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: calciphylaxis
13
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04592640·RECRUITING·Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Conditions: Chronic Kidney Diseases · Calciphylaxis · Calcific Uremic Arteriolopathy · Treatment·Matched via name phrase
- NCT04654000·RECRUITING·Rheopheresis as Adjuvant Treatment of Calciphylaxis
Conditions: Metabolic Disorder · End Stage Renal Disease · Rare Diseases·Matched via name phrase
- NCT07240649·NOT YET RECRUITING·Emerging Indications for Hyperbaric Oxygen Treatment
Conditions: Post-COVID-19 Condition · Ulcerative Colitis · Crohn Disease · Calciphylaxis·Matched via name phrase
- NCT07583745·NOT YET RECRUITING·Study of EPN-701 for the Treatment of Calciphylaxis
Conditions: Calciphylaxis·Matched via name phrase
- NCT07708038·NOT YET RECRUITING·Anti-Interleukin-6 (IL6) in Calciphylaxis
Conditions: Calciphylaxis·Matched via name phrase
- NCT05018221·RECRUITING·Better Evidence and Translation for Calciphylaxis
Conditions: Calciphylaxis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Calciphylaxis cutis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Calciphylaxis cutis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"calciphylaxis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:49:18.480Z
